Literature DB >> 31655922

Giant axonal neuropathy: a multicenter retrospective study with genotypic spectrum expansion.

Andoni Echaniz-Laguna1,2,3, Jean-Marie Cuisset4, Lucie Guyant-Marechal5, Patrick Aubourg6,7, Laurent Kremer8,9, Naziha Baaloul10, Alain Verloes11, Kouider Beladgham12, Jimmy Perrot13, Bruno Francou14, Philippe Latour13.   

Abstract

Giant axonal neuropathy (GAN) is an autosomal recessive disease caused by mutations in the GAN gene encoding gigaxonin. Patients develop a progressive sensorimotor neuropathy affecting peripheral nervous system (PNS) and central nervous system (CNS).
Methods: In this multicenter observational retrospective study, we recorded French patients with GAN mutations, and 10 patients were identified. Mean age of patients was 9.7 years (2-18), eight patients were female (80%), and all patients met infant developmental milestones and had a family history of consanguinity. Mean age at disease onset was 3.3 years (1-5), and progressive cerebellar ataxia and distal motor weakness were the initial symptoms in all cases. Proximal motor weakness and bulbar symptoms appeared at a mean age of 12 years (8-14), and patients used a wheelchair at a mean age of 16 years (14-18). One patient died at age 18 years from aspiration pneumonia. In all cases, nerve conduction studies showed a mixed demyelinating and axonal sensorimotor neuropathy and MRI showed brain and cerebellum white matter abnormalities. Polyneuropathy and encephalopathy both aggravated during the course of the disease. Patients also showed a variety of associated findings, including curly hair (100% of cases), pes cavus (80%), ophthalmic abnormalities (30%), and scoliosis (30%). Five new GAN mutations were found, including the first synonymous mutation and a large intragenic deletion. Our findings expand the genotypic spectrum of GAN mutations, with relevant implications for molecular analysis of this gene, and confirm that GAN is an age-related progressive neurodegenerative disease involving PNS and CNS.

Entities:  

Keywords:  GAN; Giant axonal neuropathy; Neurodegenerative disease

Mesh:

Substances:

Year:  2019        PMID: 31655922     DOI: 10.1007/s10048-019-00596-z

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  26 in total

1.  Identification of seven novel mutations in the GAN gene.

Authors:  P Bomont; C Ioos; C Yalcinkaya; R Korinthenberg; J M Vallat; S Assami; A Munnich; B Chabrol; G Kurlemann; M Tazir; M Koenig
Journal:  Hum Mutat       Date:  2003-04       Impact factor: 4.878

2.  Giant axonal neuropathy: clinical and genetic study in six cases.

Authors:  E Demir; P Bomont; S Erdem; L Cavalier; M Demirci; G Kose; S Muftuoglu; A N Cakar; E Tan; S Aysun; M Topcu; P Guicheney; M Koenig; H Topaloglu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

3.  A mild case of giant axonal neuropathy without central nervous system manifestation.

Authors:  Reiko Koichihara; Takashi Saito; Akihiko Ishiyama; Hirofumi Komaki; Shota Yuasa; Yoshiaki Saito; Eiji Nakagawa; Kenji Sugai; Takashi Shiihara; Ayako Shioya; Yuko Saito; Yujiro Higuchi; Akihiro Hashiguchi; Hiroshi Takashima; Masayuki Sasaki
Journal:  Brain Dev       Date:  2015-09-14       Impact factor: 1.961

4.  Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.

Authors:  Saleemulla Mahammad; S N Prasanna Murthy; Alessandro Didonna; Boris Grin; Eitan Israeli; Rodolphe Perrot; Pascale Bomont; Jean-Pierre Julien; Edward Kuczmarski; Puneet Opal; Robert D Goldman
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

5.  The absence of curly hair is associated with a milder phenotype in Giant Axonal Neuropathy.

Authors:  Lisa A Roth; Bethany L Johnson-Kerner; Jonathan D Marra; Nicole H LaMarca; Douglas M Sproule
Journal:  Neuromuscul Disord       Date:  2013-07-24       Impact factor: 4.296

6.  U1 snRNA mis-binding: a new cause of CMT1B.

Authors:  Hervé Crehalet; Philippe Latour; Véronique Bonnet; Shahram Attarian; Pierre Labauge; Nathalie Bonello; Rafaelle Bernard; Gilles Millat; Robert Rousson; Dominique Bozon
Journal:  Neurogenetics       Date:  2009-05-28       Impact factor: 2.660

7.  Kelch Domain of Gigaxonin Interacts with Intermediate Filament Proteins Affected in Giant Axonal Neuropathy.

Authors:  Bethany L Johnson-Kerner; Alejandro Garcia Diaz; Sean Ekins; Hynek Wichterle
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

8.  The instability of the BTB-KELCH protein Gigaxonin causes Giant Axonal Neuropathy and constitutes a new penetrant and specific diagnostic test.

Authors:  Alexia Boizot; Yasmina Talmat-Amar; Deborah Morrogh; Nancy L Kuntz; Cecile Halbert; Brigitte Chabrol; Henry Houlden; Tanya Stojkovic; Brenda A Schulman; Bernd Rautenstrauss; Pascale Bomont
Journal:  Acta Neuropathol Commun       Date:  2014-04-24       Impact factor: 7.801

9.  Novel homozygous missense mutation in GAN associated with Charcot-Marie-Tooth disease type 2 in a large consanguineous family from Israel.

Authors:  Sharon Aharoni; Katy E S Barwick; Rachel Straussberg; Gaurav V Harlalka; Yoram Nevo; Barry A Chioza; Meriel M McEntagart; Aviva Mimouni-Bloch; Michael Weedon; Andrew H Crosby
Journal:  BMC Med Genet       Date:  2016-11-16       Impact factor: 2.103

10.  New mutations, genotype phenotype studies and manifesting carriers in giant axonal neuropathy.

Authors:  Henry Houlden; Mike Groves; Zosia Miedzybrodzka; Helen Roper; Tracey Willis; John Winer; Gaynor Cole; Mary M Reilly
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-06-19       Impact factor: 10.154

View more
  2 in total

Review 1.  Skin Conditions and Movement Disorders: Hiding in Plain Sight.

Authors:  Kristina Kulcsarova; Janette Baloghova; Jan Necpal; Matej Skorvanek
Journal:  Mov Disord Clin Pract       Date:  2022-03-24

Review 2.  Current Clinical Applications of In Vivo Gene Therapy with AAVs.

Authors:  Jerry R Mendell; Samiah A Al-Zaidy; Louise R Rodino-Klapac; Kimberly Goodspeed; Steven J Gray; Christine N Kay; Sanford L Boye; Shannon E Boye; Lindsey A George; Stephanie Salabarria; Manuela Corti; Barry J Byrne; Jacques P Tremblay
Journal:  Mol Ther       Date:  2020-12-10       Impact factor: 11.454

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.